Skip to main content
Containers of prescription medication

It’s Time for a Public Option in the Pharmaceutical Industry

Dana Brown

Dana Brown

Director of the Next System Project more

Thomas Hanna

Thomas Hanna

Director of Research at The Democracy Collaborative more

Public Planning Democratic Ownership Health & Wellbeing

Drug companies are hated for a reason—they exist to maximize profits, not make us healthier. It’s time to put them under public control.

Drug companies are among the most widely despised businesses in America. Infamous for generating incredible profits at the expense of the sick and dying while leveraging their enormous economic power to evade regulations (to say nothing of their role in the opioid epidemic), they are often seen as a textbook profiteer. Already, many Americans report not filling prescriptions, cutting pills in half or skipping doses due to costs. In the world’s most expensive healthcare system, more than 10 percent of total healthcare costsand 21 percent of employer healthcare benefits are attributed to pharmaceuticals. Research shows that “drug spending is growing faster than any other part of the health care dollar.”

During Friday’s long-awaited speech on drug prices, President Trump blamed “foreign freeloaders”, the drug lobby and “middlemen” for rising prices, promising once again to put American patients first. However, experts predict the plan—which focuses on private sector competition and negotiation—will have little effect on the industry or its practices.

In many cases, the profits extracted by drug companies represent a form of double-taxation, given that public funding underpins pharmaceutical research and development (R&D). For instance, publicly-funded research contributed to the development of the cholesterol-lowering medication Crestor. Yet, U.S. taxpayers spent billions more (either out of pocket, through rising insurance premiums or through Medicare or Medicaid) to take the drug at marked up prices while Pharma giant AstraZeneca pulled in over $16 billion in profits on Crestor alone over a three-year period.

And that’s not all. We pay a third time when we lose revenue through tax breaks and loopholes that allow pharmaceutical companies to market their drugs to us tax-freeand operate vast networks of off-shore subsidiaries to avoid paying taxes.

In this context, and with increasing pressure to keep healthcare costs down as the population gets older, isn’t it time to consider a public option in the pharmaceutical sector? 

Read the rest of this article at In These Times

Dana Brown

Dana Brown

Director of the Next System Project more

Thomas Hanna

Thomas Hanna

Director of Research at The Democracy Collaborative more

More related work

Democratizing knowledge

Democratizing knowledge: Transforming intellectual property and research and development

We need to embed principles of democratic ownership and control to the fields of intellectual property and research and development, so that these crucial economic pillars become drivers of equity, sustainability and the common good rather than wealth inequality and concentration. read more

Understanding and seizing the momentum for public ownership

The Democracy Collaborative moderated a panel at Netroots Nation 2020 featuring three leaders of grassroots campaigns designed to advance public ownership in banking, energy and housing. read more
Biomed Europa

Biomed Europa: A challenge to the pharmaceutical oligopoly

In his new white paper, “Biomed Europa: after the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly,” Italian economist Massimo Florio proposes an international, transparent, public phar read more